全文获取类型
收费全文 | 458227篇 |
免费 | 24303篇 |
国内免费 | 802篇 |
专业分类
耳鼻咽喉 | 6338篇 |
儿科学 | 15021篇 |
妇产科学 | 14033篇 |
基础医学 | 68240篇 |
口腔科学 | 12843篇 |
临床医学 | 33508篇 |
内科学 | 91658篇 |
皮肤病学 | 10810篇 |
神经病学 | 34105篇 |
特种医学 | 15552篇 |
外国民族医学 | 45篇 |
外科学 | 65501篇 |
综合类 | 8690篇 |
现状与发展 | 1篇 |
一般理论 | 184篇 |
预防医学 | 39460篇 |
眼科学 | 11201篇 |
药学 | 33489篇 |
中国医学 | 1470篇 |
肿瘤学 | 21183篇 |
出版年
2021年 | 4678篇 |
2019年 | 5090篇 |
2018年 | 8505篇 |
2017年 | 5712篇 |
2016年 | 6135篇 |
2015年 | 6903篇 |
2014年 | 8334篇 |
2013年 | 12966篇 |
2012年 | 19063篇 |
2011年 | 19991篇 |
2010年 | 11326篇 |
2009年 | 9366篇 |
2008年 | 17333篇 |
2007年 | 18793篇 |
2006年 | 18326篇 |
2005年 | 17517篇 |
2004年 | 16637篇 |
2003年 | 15653篇 |
2002年 | 14851篇 |
2001年 | 18089篇 |
2000年 | 18981篇 |
1999年 | 15477篇 |
1998年 | 3748篇 |
1997年 | 3255篇 |
1996年 | 3106篇 |
1995年 | 2975篇 |
1992年 | 10527篇 |
1991年 | 10402篇 |
1990年 | 10223篇 |
1989年 | 9746篇 |
1988年 | 8924篇 |
1987年 | 8593篇 |
1986年 | 8241篇 |
1985年 | 7952篇 |
1984年 | 5809篇 |
1983年 | 4980篇 |
1979年 | 5619篇 |
1978年 | 4012篇 |
1977年 | 3466篇 |
1976年 | 3223篇 |
1975年 | 3685篇 |
1974年 | 4430篇 |
1973年 | 4476篇 |
1972年 | 4193篇 |
1971年 | 3976篇 |
1970年 | 3809篇 |
1969年 | 3616篇 |
1968年 | 3613篇 |
1967年 | 3306篇 |
1966年 | 3116篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
2.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
3.
4.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
5.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
6.
7.
8.
9.
Julie Despres Yasmina Ramdani Marine di Giovanni Magalie Bnard Abderrakib Zahid Mait Montero‐Hadjadje Florent Yvergnaux Thibaut Saguet Azeddine Driouich Marie‐Laure Follet‐Gueye 《Experimental dermatology》2019,28(8):922-932
It is well recognized that the world population is ageing rapidly. Therefore, it is important to understand ageing processes at the cellular and molecular levels to predict the onset of age‐related diseases and prevent them. Recent research has focused on the identification of ageing biomarkers, including those associated with the properties of the Golgi apparatus. In this context, Golgi‐mediated glycosylation of proteins has been well characterized. Additionally, other studies show that the secretion of many compounds, including pro‐inflammatory cytokines and extracellular matrix–degrading enzymes, is modified during ageing, resulting in physical and functional skin degradation. Since the Golgi apparatus is a central organelle of the secretory pathway, we investigated its structural organization in senescent primary human dermal fibroblasts using confocal and electron microscopy. In addition, we monitored the expression of Golgi‐related genes in the same cells. Our data showed a marked alteration in the Golgi morphology during replicative senescence. In contrast to its small and compact structure in non‐senescent cells, the Golgi apparatus exhibited a large and expanded morphology in senescent fibroblasts. Our data also demonstrated that the expression of many genes related to Golgi structural integrity and function was significantly modified in senescent cells, suggesting a relationship between Golgi apparatus function and ageing. 相似文献
10.
Breanne E. Kunstler Jill L. Cook Joanne L. Kemp Paul D. O’Halloran Caroline F. Finch 《Journal of Science and Medicine in Sport》2019,22(1):2-10